Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) Operating Expenses (2019 - 2025)

Historic Operating Expenses for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to -$73.4 million.

  • CureVac's Operating Expenses fell 30.27% to -$73.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $211.2 million, marking a year-over-year increase of 252.15%. This contributed to the annual value of $238.0 million for FY2024, which is 661.34% up from last year.
  • As of Q3 2025, CureVac's Operating Expenses stood at -$73.4 million, which was down 30.27% from -$68.2 million recorded in Q2 2025.
  • CureVac's 5-year Operating Expenses high stood at $1.5 billion for Q4 2021, and its period low was -$193.5 million during Q2 2021.
  • Its 5-year average for Operating Expenses is $76.4 million, with a median of -$51.0 million in 2024.
  • Data for CureVac's Operating Expenses shows a peak YoY increase of 34424.58% (in 2021) and a maximum YoY decrease of 18027664.71% (in 2021) over the last 5 years.
  • Over the past 5 years, CureVac's Operating Expenses (Quarter) stood at $1.5 billion in 2021, then tumbled by 80.54% to $285.3 million in 2022, then skyrocketed by 33.46% to $380.8 million in 2023, then increased by 7.56% to $409.6 million in 2024, then crashed by 117.92% to -$73.4 million in 2025.
  • Its Operating Expenses was -$73.4 million in Q3 2025, compared to -$68.2 million in Q2 2025 and -$56.8 million in Q1 2025.